Here, we identify casein kinase 1 delta (CSNK1D) as positive regulator of oncogenic GLI function and show that pharmacological as well as genetic targeting of CSNK1D is sufficient to abrogate HH—GLI signaling in both SMOi-sensitive and SMOi-resistant cancer cells driven by oncogenic GLI. This evidence concerns the gene GLI1 and cancer.